Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Katharine Batt"'
Autor:
Kevin Chiu, Joanna P. MacEwan, Suepattra G. May, Katalin Bognar, Desi Peneva, Lauren M. Zhao, Candice Yong, Suvina Amin, Bjorn Bolinder, Katharine Batt, James R. Baumgardner
Publikováno v:
MDM Policy & Practice, Vol 7 (2022)
Background. Traditional approaches to capturing health-related productivity loss (e.g., the human capital method) focus only on the foregone wages of affected patients, overlooking the losses caregivers can incur. This study estimated the burden of p
Externí odkaz:
https://doaj.org/article/48199a136b564ac98ab0d8b16426e573
Autor:
Anshu Shrestha, Jun Su, Nanxin Li, Christopher Barnowski, Nisha Jain, Katie Everson, Anupam Bapu Jena, Katharine Batt
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 1, Pp 94-103 (2021)
Abstract Background Few have assessed physical activity (PA) and annual bleed rates (ABRs) among people with hemophilia on extended half‐life (EHL) factors (recombinant factor VIII Fc [rFVIIIFc]/recombinant factor IX Fc [rFIXFc]) and conventional f
Externí odkaz:
https://doaj.org/article/be1379d6d7004cd392f12f67c301d97b
Publikováno v:
BMC Medical Research Methodology, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Long-term clinical outcomes are necessary to assess the cost-effectiveness of new treatments over a lifetime horizon. Without long-term clinical trial data, current practice to extrapolate survival beyond the trial period involves
Externí odkaz:
https://doaj.org/article/15c2d681f38241fc882a54d1254da5b1
Autor:
Joanna P. MacEwan, Jason Doctor, Karen Mulligan, Suepattra G. May, Katharine Batt, Christopher Zacker, Darius Lakdawalla, Dana Goldman
Publikováno v:
MDM Policy & Practice, Vol 4 (2019)
Background. Value assessments and treatment decision making typically focus on clinical endpoints, especially overall survival (OS). However, OS data are not always available, and surrogate markers may also have some value to patients. This study sou
Externí odkaz:
https://doaj.org/article/0fe563d13e384851bcf374f400586c87
Autor:
Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Publikováno v:
Haemophilia. 29:809-818
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82b975f69201adfb87bb23512d129f3a
https://doi.org/10.1111/hae.14794
https://doi.org/10.1111/hae.14794
Publikováno v:
Clinical Transplantation.
This study aimed to characterize patient risk groups and respective prognostic profiles to optimize clinical decision-making and guide appropriate medical CMV management among patients with solid organ transplant (SOT).Between 9/2021 and 2/2022, a 3-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3409dc67be1d0bfd331b8185ddece026
https://doi.org/10.1111/ctr.14905
https://doi.org/10.1111/ctr.14905
Autor:
W Allan, Alexander, Ivar, Jensen, Joanne, Hathway, Krutika, Srivastava, Philip, Cyr, Robert F, Sidonio, Katharine, Batt
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 28:518-527
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ded698d644708519cc32ebb687473af
https://doi.org/10.18553/jmcp.2022.21197
https://doi.org/10.18553/jmcp.2022.21197
Autor:
Michael Bullano, Christina Cool, Bob G. Schultz, Sneha Durgapal, Naomi Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
To evaluate the financial impact of utilizing rpFVIII or rFVIIa during a hospital admission for the diagnosis of acquired hemophilia A (AHA) by reviewing the margin between the cost to the hospital for providing care and the amount the hospital is re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4119e62a84018a7e9851621e1424acd0
Autor:
Marlon Graf, Michael Recht, Rifat Tuly, Sreenivas P Veeranki, Priti P. Pednekar, Katharine Batt
Publikováno v:
Journal of Blood Medicine
Sreenivas P Veeranki,1 Priti Pednekar,1 Marlon Graf,1 Rifat Tuly,1 Michael Recht,2,3 Katharine Batt1 1PRECISIONheor, Los Angeles, CA, USA; 2American Thrombosis and Hemostasis Network, Rochester, NY, USA; 3The Hemophilia Center, Oregon Health & Scienc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b65f2b5b7239e77d73e9f6914b93e37
http://europepmc.org/articles/PMC8544791
http://europepmc.org/articles/PMC8544791
Autor:
Katharine Batt, Michael Bullano, Bob G Schultz, Yanmei Liu, Rebecca Kee, Carolyn Harley, Christina Cool
Publikováno v:
Future Rare Diseases. 2
Objective: To compare mortality and readmission rates for patients with acquired hemophilia A (AHA) who were observed to use activated recombinant factor VII (rFVIIa) and/or recombinant porcine factor VIII (rpFVIII) during a hospital admission. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4b02d1343b3386491d60dbbd327bd24
https://doi.org/10.2217/frd-2022-0005
https://doi.org/10.2217/frd-2022-0005